Top

European Archives of Oto-Rhino-Laryngology

Published in:

26-06-2023 | Allergic Rhinitis | Rhinology

Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons

Authors: Jiayi Yang, Weidong Wang, Zhen Shen, Wei Kang, Pengfei Zhang, Xin Chen, Huajing Li, Yuan Shao, Lifeng Liu, Shaoqiang Zhang, Fang Quan

Published in: European Archives of Oto-Rhino-Laryngology | Issue 11/2023

Abstract

Objective

This study investigates the efficacy and safety of sublingual immunotherapy (SLIT) with A. annua allergens in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons.

Methods

Seventy patients with moderate-severe seasonal allergic rhinoconjunctivitis were divided evenly into the SLIT and control groups. The SLIT last from 3 months before the summer-autumn pollen season in 2021 till the end of the summer-autumn pollen season in 2022. The daily individual symptom score, total rhinoconjunctivitis symptom score (dTRSS), total medication score (dTMS), combined score of medication and rhinoconjunctivitis symptom (dCSMRS), visual analog scale (VAS) score, and adverse events (AEs) were evaluated.

Results

The average pollen concentration in 2022 was twice that previous two-year during the pollen season. Fifty-six patients completed treatments (SLIT group: 29, control group: 27). Compared with baseline, the individual symptoms, dTRSS, dTMS, dCSMRS, and VAS scores of SLIT group declined in 2021. After 16 months of SLIT, all efficacy indexes in 2022 were still lower than baseline and equivalent to those in 2021. In control group, the efficacy indexes in 2022 were higher than that in 2020 and 2021. The efficacy indexes of SLIT group were lower than those of control group in 2021 and 2022. SLIT is effective for both mono- and poly-sensitized patients. AEs incidence in SLIT group was 82.7% without severe AEs.

Conclusions

The A. annua-SLIT can obtain efficacy and safety over two pollen seasons for patients with moderate-severe seasonal allergic rhinoconjunctivitis.

Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis (2022, revision). Chin J Otorhinolaryngol Head Neck Surg, 2022,57(02):106–129

Deng ZY, Liu XJ, Sa RN et al (2021) Epidemiological investigation of allergic rhinitis in central cities and countrysides of Inner Mongolia region. Chin J Otorhinolaryngol Head Neck Surg 56(06):635–642

Gotoh M, Yonekura S, Imai T et al (2019) Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet. J Allergy Clin Immunol Pract 7(4):1287-1297.e8. https://doi.org/10.1016/j.jaip.2018.11.044CrossRefPubMed

Wang XY, Ma TT, Wang XY et al (2018) Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy 73(6):1232–1243CrossRefPubMed

Roberts G, Pfaar O, Akdis CA et al (2018) EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy 73(4):765–798CrossRefPubMed

Li H, Chen S, Cheng L et al (2019) Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma. J Thorac Dis 11(12):4936CrossRefPubMedPubMedCentral

Halken S, Larenas-Linnemann D, Roberts G et al (2017) EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 28(8):728–745CrossRefPubMed

Liu X, Ng CL, Wang DY (2018) The efficacy of sublingual immunotherapy for allergic diseases in Asia. Allergol Int 67(3):309–319CrossRefPubMed

Cheng L, Zhou WC (2019) Sublingual immunotherapy of house dust mite respiratory allergy in China. Allergol Immunopathol (Madr) 47(1):85–89CrossRefPubMed

10.

Lou H, Wang X, Wei Q et al (2020) Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trial. World Allergy Organ J 13(9):100458CrossRefPubMedPubMedCentral

11.

Leonardi A, Castegnaro A, Valerio ALG et al (2015) Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol 15(5):482–488CrossRefPubMed

12.

Lou H, Ma S, Zhao Y et al (2017) Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China. Sci Rep 7(1):9286CrossRefPubMedPubMedCentral

13.

Gao Z, Fu WY, Sun Y et al (2019) Artemisia pollen allergy in China: Component-resolved diagnosis reveals allergic asthma patients have significant multiple allergen sensitization. Allergy 74(2):284–293CrossRefPubMed

14.

Lou H, Huang Y, Ouyang Y et al (2020) Artemisia annua -sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial. Allergy 75(8):2026–2036CrossRefPubMed

15.

Yang J, Shen Z, Liu L et al (2022) Clinical efficacy and safety of Artesimia annua-sublingual immunotherapy in seasonal allergic rhinitis patients based on different intervention time. Int Arch Allergy Immunol 183(8):852–859CrossRefPubMed

16.

Okubo K, Kurono Y, Fujieda S et al (2011) Japanese guideline for allergic rhinitis. Allergol Int 60(2):171–189CrossRefPubMed

17.

Ouyang YH, Zhao LP, Zhang L (2013) Relationship of pollinosis onset patterns and atmospheric pollen species and concentration. Journal of Capital Medical University 34(06):805–807

18.

Prince A, Norris MR, Bielory L (2018) Seasonal ocular allergy and pollen counts. Curr Opin Allergy Clin Immunol 18(5):387–392CrossRefPubMed

19.

Takamura E, Uchio E, Ebihara N et al (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66(2):220–229CrossRefPubMed

20.

Pfaar O, Bastl K, Berger U et al (2017) Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper. Allergy 72(5):713–722CrossRefPubMed

21.

Zuberbier T, Bachert C, Bousquet PJ et al (2010) GA²LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma: GA²LEN/EAACI pocket guide. Allergy 65(12):1525–1530CrossRefPubMed

22.

Brożek JL, Bousquet J, Baena-Cagnani CE et al (2010) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126(3):466–476CrossRefPubMed

23.

Wang XD, Zheng M, Lou HF et al (2016) An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy 71(8):1170–1180CrossRefPubMed

24.

Meng J, Xu R, Ye J et al (2022) Expert consensus on classification and diagnosis of allergic rhinitis(2022, Chengdu). Chin J Ophthalmol and Otorhinolaryngol 22(3):10

25.

Creticos PS, Esch RE, Couroux P et al (2014) Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 133(3):751–758CrossRefPubMed

26.

Jerzynska J, Stelmach W, Majak P et al (2018) Comparison of the effect of 5-grass pollen sublingual immunotherapy tablets and drops in children with rhinoconjunctivitis. Allergy Asthma Proc 39(1):66–73CrossRefPubMed

27.

Okamoto Y, Okubo K, Yonekura S et al (2015) Efficacy and safety of sublingual immunotherapy for two seasons in patients with japanese cedar pollinosis. Int Arch Allergy Immunol 166(3):177–188CrossRefPubMed

28.

San Nicoló M, Högerle C, Gellrich D et al (2021) Relevance of major allergens in weed pollen allergy. Int Arch Allergy Immunol 182(7):637–641CrossRefPubMed

29.

Dai L, Liu J, Zhao Q et al (2022) Investigation of allergic sensitizations in children with allergic rhinitis and/or asthma. Front Pediatr 10:842293CrossRefPubMedPubMedCentral

30.

Nelson H, Blaiss M, Nolte H et al (2013) Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 68(2):252–255CrossRefPubMed

31.

Thomas WR (2010) Geography of house dust mite allergens. Asian Pac J Allergy Immunol 28(4):211–224PubMed

32.

Matsuoka T, Kobayashi S, Ohashi-Doi K, et al. Immunological changes over three years treatment with Japanese cedar SLIT drops in mono-sensitized and poly-sensitized individuals. Allergol Int. 2022,71(3):405–408

33.

Zhang Y, Luo J, Wang Z et al (2019) Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. Am J Otolaryngol 40(5):755–760CrossRefPubMed

34.

Cox L, Jacobsen L (2009) Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 103(6):451–460CrossRefPubMed

35.

Lou H, Zhang L (2020) The allergen⁃specific immunotherapy for allergic rhinitis. Chin J Otorhinolaryngol Head Neck Surg 55(5):7

Title: Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons
Authors: Jiayi Yang
Weidong Wang
Zhen Shen
Wei Kang
Pengfei Zhang
Xin Chen
Huajing Li
Yuan Shao
Lifeng Liu
Shaoqiang Zhang
Fang Quan
Publication date: 26-06-2023
Publisher: Springer Berlin Heidelberg
Keywords: Allergic Rhinitis
Conjunctivitis
Allergen-Specific Immunotherapy
Allergen-Specific Immunotherapy
Published in: European Archives of Oto-Rhino-Laryngology / Issue 11/2023
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08078-7

2024 ASCO Annual Meeting

Springer Medicine

Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons

Abstract

Objective

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2023

Computational fluid dynamics calculations in inferior turbinate surgery: a cohort study

Salivary gland pathologies: evolution in classification and association with unique genetic alterations

Transoral removal of submandibular hilar lithiasis: results on the salivary duct system, glandular parenchyma, and quality-of-life recovery

Xerostomia, sticky saliva and dysphonia

Prevalence and risk factors of hearing loss among the middle-aged and older population in China: a systematic review and meta-analysis

Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial